Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.39 |
| ▸ | C5 | P01031 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416106 | 0.93 | SMPD1 (0.43) | L3MBTL1MAPK1SMPD1C5S1PR2 | |
| SCHEMBL2412575 | 0.85 | LMNA (0.52) | L3MBTL1MAPK1 | |
| SCHEMBL2416686 | 0.85 | ALOX15 (0.49) | PPARAFAAH | |
| SCHEMBL2416924 | 0.83 | MAPT (0.45) | PPARAMAPK1FAAH | |
| SCHEMBL5699358 | 0.83 | MAPT (0.45) | PPARAMAPK1FAAH | |
| SCHEMBL2417275 | 0.81 | PSMB11 (0.48) | PPARAMAPK1FAAH | |
| SCHEMBL2417274 | 0.81 | PSMB11 (0.48) | PPARAMAPK1FAAH | |
| SCHEMBL7272322 | 0.78 | SMPD1 (0.51) | SMPD1 | |
| SCHEMBL2421065 | 0.77 | LMNA (0.59) | L3MBTL1MAPK1 | |
| SCHEMBL5496986 | 0.77 | LMNA (0.46) | L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011109525-A1 | Aging-Related Circulating Particle-Associated Lipoprotein B Oxidase (apoBNOX) and Inhibitors Thereof | NOX TECHNOLOGIES, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1494658-B1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH SA (ES) | 2006-01-04 | — | — | EP | disclosed |
| EP-1494658-A1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH, S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| US-20030236202-A1 | Natural products and derivatives thereof for protection against neurodegenerative diseases | PULEVA BIOTECH, S.A. (ES) | 2003-12-25 | — | — | US | disclosed |
| WO-2003082259-A1 | NATURAL PHENOLIC PRODUCTS AND DERIVATIVES THEREOF FOR PROTECTION AGAINST NEURODEGENERATIVE DISEASES | PULEVA BIOTECH, S.A. (ES) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236202-A1 | Natural products and derivatives thereof for protection against neurodegenerative diseases | SNCA, HTT, PARK7 | PPARA 279/4885L3MBTL1 1558/4885MAPK1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.